Overview
At ADARx, we are committed to better outcomes for patients. We leverage our innovative RNA therapeutic approach with a goal of providing highly effective and convenient treatments addressing unmet needs across a broad range of diseases, including genetic, complement-mediated, cardiometabolic and central nervous system diseases.
Patients are at the center of everything we do, and we work with urgency knowing that we have the potential to improve the lives of patients.
Clinical Trials
Advancements in RNA medicines would not be possible without participation from patients in clinical trials. Learn more about our ongoing clinical trials below:
STOP-HAE: A Phase 3 Study of ADX-324 in HAE (STOP-HAE)
Recruiting Status: Active, not recruiting
Age: 18 – 65 Years Old
STOP-HAE: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema
Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients
Recruiting Status: Active, not recruiting
Age: 18 – 65 Years Old
A Phase 1, Randomized, Placebo-Controlled, Double-Blind Study in Healthy Volunteers and a Phase 2a, Open-Label Study in Patients with Hereditary Angioedema to Evaluate the Safety, Tolerability, PK and PD of ADX-324.
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
Recruiting Status: Recruiting
Age: 18 – 65 Years Old
This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
Recruiting Status: Recruiting
Age: 18 – 65 Years Old
Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assessed.
Safety, Tolerability, PK and PD of ADX-038 in HV and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
Recruiting Status: Active, not recruiting
Age: 18 – 65 Years Old
The first-in-human Phase 1/Phase 2a study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in both healthy participants (HP) and in patients with paroxysmal nocturnal hemoglobinuria (PNH).
Phase 1 Study of ADX-626 in Healthy Participants
Recruiting Status: Recruiting
Age: 18 – 45 Years Old
This first-in-human study will evaluate the safety and tolerability of ADX-626 in healthy participants. The study will also look at how ADX-626 interacts with the human body (the pharmacokinetics and pharmacodynamics of ADX-626).
Safety, Tolerability, PK and PD of ADX-850 in Participants with Hypertension
Recruiting Status: Active, not recruiting
Age: 18 – 65 Years Old
The first-in-human Phase 1 study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ADX-850 in patients with hypertension.
